Invivyd (IVVD) Stock
Clinical stage biotech developing immune system treatments. Here's the price, business snapshot, and what's worth knowing about Invivyd in October 2026.
Invivyd Inc (IVVD) is a small‑cap, clinical‑stage biotechnology company (market cap ~US$427M) focused on developing immune‑modulating therapies. The business is centred on research and development, with value driven primarily by clinical milestones, regulatory decisions, licensing deals and potential partnerships rather than steady product revenue. For investors, key considerations include the stage of the pipeline, trial readouts, cash runway and intellectual property. As with many biotech names, share prices can be volatile around clinical data and corporate updates. This summary is educational and not personalised investment advice. Prospective investors should review the company’s regulatory filings, recent investor presentations and clinical data, and consider speaking with a qualified financial adviser. Remember that biotechnology investing carries higher uncertainty: values can rise and fall and past performance is not indicative of future results.
Invivyd (IVVD) Stock Forecast
Analyst price target, next 12 months
$10.00
+1116.4% vs today's $0.82
Price range over the last 12 months
Close to its 12-month low
Analysts covering Invivyd have a consensus 12-month target of $10.00, above the current price of $0.82.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 30 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying INVIVYD INC's stock with a target price of $10, indicating strong growth potential.
Financial Health
INVIVYD INC is generating strong revenue and profit margins, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical‑stage pipeline
Investor attention often centres on trial milestones and data readouts, which can materially affect value; outcomes are uncertain and may be binary.
Scientific approach
The company’s scientific strategy may offer differentiated mechanisms or targets, but early‑stage science carries translational and regulatory risk.
Partnership potential
Successful alliances or licensing can de‑risk development and provide funding, though such deals are not guaranteed and depend on clinical progress.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
